$21.14
-1.07-4.82%
At Close: -
$21.14
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Jasper Therapeutics
JSPRNASDAQ
want to know what
the Bulls & Bears Say?
Jasper Therapeutics (NASDAQ:JSPR) Stock, Analyst Ratings, Price Targets, Forecasts
Jasper Therapeutics Inc has a consensus price target of $31.76 based on the ratings of 37 analysis. The 3 most-recent analyst ratings were released by Stifel, HC Wainwright & Co., and HC Wainwright & Co. on June 27, 2024, May 20, 2024, and May 15, 2024, respectively. With an average price target of $72 between Stifel, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 240.59% upside for Jasper Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Cantor Fitzgerald
HC Wainwright & Co.
Evercore ISI Group
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Jasper Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2024 | Buy Now | 306.81% | Stifel | Ben Burnett | → $86 | Initiates | → Buy | Get Alert |
| 06/18/2024 | Buy Now | — | Cantor Fitzgerald | Pete Stavropoulos | — | Reiterates | → Overweight | Get Alert |
| 05/20/2024 | Buy Now | 207.47% | HC Wainwright & Co. | Emily Bodnar | → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 207.47% | HC Wainwright & Co. | Emily Bodnar | → $65 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 207.47% | HC Wainwright & Co. | Emily Bodnar | → $65 | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | 207.47% | Evercore ISI Group | Gavin Clark-Gartner | → $65 | Initiates | → Outperform | Get Alert |
| 03/28/2024 | Buy Now | 231.13% | RBC Capital | Gregory Renza | → $70 | Initiates | → Outperform | Get Alert |
| 03/18/2024 | Buy Now | — | TD Cowen | Yaron Werber | — | Initiates | → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 278.43% | Oppenheimer | Jay Olson | $80 → $80 | Maintains | Outperform | Get Alert |
| 10/12/2023 | Buy Now | -71.62% | Cantor Fitzgerald | Pete Stavropoulos | → $60 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2023 | Buy Now | -81.08% | Credit Suisse | Judah Frommer | → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 08/11/2023 | Buy Now | -66.89% | Capital One | Tim Chiang | → $70 | Initiates | → Overweight | Get Alert |
| 06/12/2023 | Buy Now | -67.6% | EF Hutton | Michael King | → $68.5 | Reiterates | Buy → Buy | Get Alert |
| 05/25/2023 | Buy Now | -67.6% | EF Hutton | Michael King | → $68.5 | Assumes | → Buy | Get Alert |
| 05/16/2023 | Buy Now | -62.16% | Oppenheimer | Jay Olson | → $80 | Reinstates | Outperform → Outperform | Get Alert |
| 05/15/2023 | Buy Now | -67.6% | EF Hutton | Michael King | → $68.5 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | -81.08% | Credit Suisse | Judah Frommer | → $40 | Reiterates | Outperform → Outperform | Get Alert |
| 03/09/2023 | Buy Now | -67.6% | EF Hutton | Michael King | → $68.5 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | -71.62% | Cantor Fitzgerald | Pete Stavropoulos | → $60 | Reiterates | → Overweight | Get Alert |
| 03/09/2023 | Buy Now | -81.08% | Credit Suisse | Judah Frommer | → $40 | Reiterates | → Outperform | Get Alert |
| 02/27/2023 | Buy Now | -67.6% | EF Hutton | Michael King | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/21/2023 | Buy Now | -67.6% | EF Hutton | Michael King | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/17/2023 | Buy Now | -67.6% | EF Hutton | Michael King | → $68.5 | Reiterates | → Buy | Get Alert |
| 02/16/2023 | Buy Now | -67.6% | EF Hutton | Michael King | $40 → $68.5 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | -71.62% | Cantor Fitzgerald | Pete Stavropoulos | $100 → $60 | Reiterates | → Overweight | Get Alert |
| 01/11/2023 | Buy Now | -85.81% | Credit Suisse | Judah Frommer | $70 → $30 | Maintains | Outperform | Get Alert |
| 01/11/2023 | Buy Now | -81.08% | EF Hutton | Michael King | → $40 | Maintains | Buy | Get Alert |
| 11/14/2022 | Buy Now | -62.16% | Oppenheimer | Jay Olson | $210 → $80 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | -81.08% | EF Hutton | Michael King | → $40 | Initiates | → Buy | Get Alert |
| 07/13/2022 | Buy Now | -62.16% | Credit Suisse | Judah Frommer | $90 → $80 | Maintains | Outperform | Get Alert |
| 05/13/2022 | Buy Now | -57.43% | Credit Suisse | Judah Frommer | $100 → $90 | Maintains | Outperform | Get Alert |
| 02/28/2022 | Buy Now | -52.7% | Cantor Fitzgerald | Pete Stravropoulos | → $100 | Initiates | → Overweight | Get Alert |
| 02/25/2022 | Buy Now | -52.7% | Credit Suisse | Judah Frommer | $150 → $100 | Maintains | Outperform | Get Alert |
| 11/08/2021 | Buy Now | -29.04% | Credit Suisse | Judah Frommer | → $150 | Initiates | → Outperform | Get Alert |
| 10/21/2021 | Buy Now | — | William Blair | Matt Phipps | — | Initiates | → Outperform | Get Alert |
| 10/20/2021 | Buy Now | -10.12% | BMO Capital | Matthew Luchini | → $190 | Initiates | → Outperform | Get Alert |
| 10/13/2021 | Buy Now | -0.66% | Oppenheimer | Jay Olson | → $210 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Jasper Therapeutics (JSPR) stock?
The latest price target for Jasper Therapeutics (NASDAQ:JSPR) was reported by Stifel on June 27, 2024. The analyst firm set a price target for $86.00 expecting JSPR to rise to within 12 months (a possible 306.81% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jasper Therapeutics (JSPR)?
The latest analyst rating for Jasper Therapeutics (NASDAQ:JSPR) was provided by Stifel, and Jasper Therapeutics initiated their buy rating.
When was the last upgrade for Jasper Therapeutics (JSPR)?
There is no last upgrade for Jasper Therapeutics
When was the last downgrade for Jasper Therapeutics (JSPR)?
There is no last downgrade for Jasper Therapeutics.
When is the next analyst rating going to be posted or updated for Jasper Therapeutics (JSPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on June 27, 2024 so you should expect the next rating to be made available sometime around June 27, 2025.
Is the Analyst Rating Jasper Therapeutics (JSPR) correct?
While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a initiated with a price target of $0.00 to $86.00. The current price Jasper Therapeutics (JSPR) is trading at is $21.14, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.